

MONDAY, OCTOBER 12- ALFA HALL

TIME	SYMPOSIUM	COMPANY
14:30 – 15:30	INDUSTRY SATELLITE SYMPOSIUM 1	SANOFI

TUESDAY, OCTOBER 13 - ALFA HALL

TIME	SYMPOSIUM	COMPANY
12:15 - 13:15	Are Long-Term Data Changing Our Perspectives On Advanced Melanoma Treatment?	BMS
12:15 – 12:20	Welcome and Introduction Olivier Michielin (Lausanne, Switzerland)	
12:20 – 12:35	Landmarks and More: A Review of Long-Term Outcomes Helen Gogas (Athens, Greece)	
12:35 – 12:50	How are Long-Term Outcomes Impacting Our Practice and Opinions? Reinhard Dummer (Zurich, Switzerland)	
12:50 – 13:10	Q&A and Interactive Workshop All faculty	
13:10 – 13:15	Summary and Close Olivier Michielin (Lausanne, Switzerland)	
14:30 – 15:30	INDUSTRY SATELLITE SYMPOSIUM 2 Evolution in CTCL: a new therapeutic landscape	Kyowa Kirin International plc
14:30 – 14:35	Welcome and introduction Prof. Chalid Assaf (Aachen, Germany)	
14:30 – 14:55	The patient journey from diagnosis to prognosis Prof. Chalid Assaf (Aachen, Germany)	
14:55 – 15:15	The evolving landscape for systemic treatments in CTCL: implications for practice Prof. Richard Cowan (Manchester, UK)	
15:15 – 15:30	Panel discussion and summary Prof. Chalid Assaf (Aachen, Germany), Prof. Chalid Assaf (Aachen, Germany)	
16:00 – 17:00	Advanced CSCC: What to Do When Surgery Just Isn't Going to Cut It	Regeneron
16:00 – 16:10	Opening Remarks & Introductions Badri Modi, MD	
16:10 – 16:30	Panel Discussion 1 — Immunotherapy in Advanced CSCC: Rationale Badri Modi, MD; Irene Braña, MD, PhD; Victor Moreno, MD, PhD	
16:30 – 16:50	Panel Discussion 2 — Incorporating Immunotherapy into Practice: Safety, Patient Selection, and Emerging Therapies Badri Modi, MD; Irene Braña, MD, PhD; Victor Moreno, MD, PhD	
16:50 – 17:00	Closing Remarks & Audience Questions Badri Modi, MD; Irene Braña, MD, PhD; Victor Moreno, MD, PhD	

WEDNESDAY, OCTOBER 14 - ALFA HALL

TIME	SYMPOSIUM	COMPANY
12:15 – 13:15	INDUSTRY SATELLITE LUNCH SYMPOSIUM 2	Novartis
14:30 – 15:30	TARGETING BRAF MUTATIONS IN ADVANCED MELANOMA	PIERRE FABRE
14.30 – 14.35	Welcome and introduction Dirk Schadendorf (Essen, Germany)	
14.35 – 14.45	Clinical trial experience: What can we expect from BRAF/MEK inhibition in advanced melanoma? <i>Clinical case</i> Mario Mandalà (Bergamo, Italy)	
14.45 – 15.05	Emerging sequencing approaches Caroline Robert (Paris, France)	
15.05 – 15.15	Clinical trial experience: Treatment sequencing in advanced melanoma <i>Clinical case</i> Piotr Rutkowski (Warsaw, Poland)	
15.15 – 15.25	Panel discussion: Evolving strategies and future perspectives All faculty	
15.25 – 15.30	Closing remarks Dirk Schadendorf (Essen, Germany)	